Here you will find the recommendations we have made about the use of individual medicines in Lancashire.


Brand: Enbrel ┬«, Benepali┬«
Indication: Juvenile Idiopathic Arthritis (JIA) in Adult Patients
Disease category: Musculoskeletal & Joint Diseases
Commissioning responsibility: CCG
PbR excluded: Yes


Treatment with Etanercept for adult patients with JIA is recommended in Lancashire in the following circumstances:
-Young people with JIA currently being treated with one of the agents and transferring over from adolescent to adult services
- Patients with JIA whose disease becomes active during adult life
- Patients with JIA requiring a biologic agent to be reinstated (e.g. after a period of remission or pregnancy)
In the above circumstances treatment is only recommended if the following criteria are met:
1. Treatment was in line with NICE TA238 or TA373 before transfer to adult services OR is in line with NICE TA238 or TA373 (with the exception of any age restrictions) for newly treated patients. For continuation into adulthood, if treatment was not in line with a NICE TA, the patient may continue to receive treatment until the prescribing clinician feels this may be stopped.


LMMG recommendation: Red
Click here to find the definitions for the colour classifications

Reason for decision:  Specialist medicine

Supporting documents:

Biological Agents For Treating JIA In Adult Patients (Version 2.0) (208.7 KiB)

Biosimilars of Etanercept (Version 1.0) (268.5 KiB)

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG